Immunovant Inc. (IMVT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Immunovant Inc. (IMVT) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How IMVT Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $4.00B | 0% | -14.9% | -$505.6M | -$407.3M | -45% |
| FY 2024 | $4.00B | 0% | -12.2% | -$413.8M | -$376.6M | -45% |
| FY 2023 | $4.00B | 0% | -7.7% | -$259.3M | -$214.2M | -11.9% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring IMVT)
- ✓Live walkthrough of IMVT's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
IMVT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +9.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IMVT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IMVT. Explore sector supply chains on /butterfly.
IMVT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Immunovant Inc. (IMVT)?
In FY 2025 (10-K), IMVT converted $4.0B of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).